Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2- (phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5063-5072

  Magee, Wendy C ^a   Valiaeva, Nadejda ^b,c   Beadle, James R ^b,c   Richman, Douglas D ^b,c   Hostetler, Karl Y ^b,c   Evans, David H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 HYDROXY 2 (PHOSPHONOMETHOXYPROPYL)]CYTOSINE OCTADECYLOXYETHYL ESTER; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXYPROPYL)]DIAMINOPURINE OCTADECYLOXYETHYL ESTER; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXYPROPYL)]GUANINE OCTADECYLOXYETHYL ESTER; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXYPROPYL)]THYMINE OCTADECYLOXYETHYL ESTER; 9 [3 METHOXY 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE OCTADECYLOXYETHYL ESTER; ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; ESTER DERIVATIVE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DNA TEMPLATE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN FIBROBLAST; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; CELL SURVIVAL; HIV-1; HUMANS; MOLECULAR STRUCTURE; NUCLEOSIDES;

EID: 80054696791     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05161-11     Document Type: Article

References (34)

1. 14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681.
2. Andrei, G., et al. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80:9391-9401. (Pubitemid 44435618)
3. Baker, R. O., M. Bray, and J. W. Huggins. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 57:13-23. (Pubitemid 36254717)
4. Balzarini, J., et al. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2- phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37:332-338. (Pubitemid 23046579)
5. Beadle, J. R., et al. 2002. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46:2381-2386. (Pubitemid 34793439)
6. Beadle, J. R., et al. 2006. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J. Med. Chem. 49:2010-2015.
7. Cherrington, J. M., et al. 1996. Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases. Antimicrob. Agents Chemother. 40:1270-1273. (Pubitemid 26136048)
8. Deayton, J. R., et al. 2004. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363:2116-2121. (Pubitemid 38844151)
9. De Clercq, E., and A. Holý. 2005. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4:928-940. (Pubitemid 41637695)
10. De Clercq, E., et al. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467. (Pubitemid 16026278)
11. De Clercq, E., et al. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:261-272. (Pubitemid 18073222)
12. Domaoal, R. A., et al. 2008. Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem. 283:5452-5459.
13. Frangeul, A., et al. 2008. Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. Antivir. Ther. 13:115-124. (Pubitemid 351541681)
14. Gilbert, D. N., R. C. Moellering, Jr., G. M. Eliopoulos, H. F. Chambers, and M. S. Saag. 2010. The Sanford guide to antimicrobial therapy, 40th ed. Antimicrobial Therapy, Inc., Sperryville, VA.
15. Hammond, J. L., et al. 2001. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrob. Agents Chemother. 45:1621-1628. (Pubitemid 32466326)
16. Hostetler, K. Y. 2009. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res. 82:A84-A98.
17. Hostetler, K. Y., K. A. Aldern, W. B. Wan, S. L. Ciesla, and J. R. Beadle. 2006. Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl] adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 50:2857-2859. (Pubitemid 44198714)
18. Jabs, D. A., et al. 2005. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 112:771-779. (Pubitemid 40631495)
19. Japour, A. J., et al. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101. (Pubitemid 23141326)
20. Julien, O., et al. 2011. Solution structure of a DNA duplex containing the potent anti-poxvirus agent cidofovir. J. Am. Chem. Soc. 133:2264-2274.
21. Kornbluth, R. S., et al. 2006. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 50:4038-4043. (Pubitemid 44865147)
22. Lanier, R., et al. 2010. Development of CMX001 for the treatment of poxvirus infections. Viruses 2:2740-2762.
23. Magee, W. C., K. A. Aldern, K. Y. Hostetler, and D. H. Evans. 2008. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 52:586-597. (Pubitemid 351170832)
24. Magee, W. C., K. Y. Hostetler, and D. H. Evans. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49:3153-3162. (Pubitemid 41060553)
25. Naeger, D. M., et al. 2010. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 5:e8886.
26. Painter, G. R., et al. 2007. Evaluation of hexadecyloxypropyl-9-R-[2- (phosphonomethoxy) propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother. 51:3505-3509. (Pubitemid 47519336)
27. Pauwels, R., et al. 1988. Phosphonomethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1025-1030.
28. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
29. Srinivas, R. V., M. Connely, and A. Fridland. 1997. (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes. Antiviral Res. 35:23-27. (Pubitemid 27261203)
30. Tchesnokov, E. P., A. Obikhod, R. F. Schinazi, and M. Götte. 2008. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J. Biol. Chem. 283:34218-34228.
31. Valiaeva, N., et al. 2009. Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Res. 84:254-259.
32. Valiaeva, N., et al. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2- (phosphonomethoxy)propyl] nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg. Med. Chem. 19:4616-4625.
33. Wong, J. L., and D. S. Fuchs. 1970. Competitive isomerization and dealkylation of 2,4-dialkoxypyrimidines in aqueous and nonaqueous media. J. Org. Chem. 35:3786-3791.
34. Xiong, X., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599. (Pubitemid 27098410)